- Previous Close
15.45 - Open
15.16 - Bid --
- Ask --
- Day's Range
14.40 - 16.02 - 52 Week Range
5.40 - 32.55 - Volume
75,313 - Avg. Volume
43,274 - Market Cap (intraday)
17.059M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.80 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.00
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
www.cadrenal.comRecent News: CVKD
View More
Performance Overview: CVKD
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVKD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVKD
View MoreValuation Measures
Market Cap
18.02M
Enterprise Value
12.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-91.90%
Return on Equity (ttm)
-174.01%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.24M
Diluted EPS (ttm)
-4.80
Balance Sheet and Cash Flow
Total Cash (mrq)
5.04M
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
-2.54M
Research Analysis: CVKD
View MoreCompany Insights: CVKD
CVKD does not have Company Insights